US venture capital firms raised $10.3bn during the second quarter of 2015 – the highest quarterly total since the fourth quarter of 2007, according to the National Venture Capital Association (NVCA) – and roughly $2bn of the newly raised cash may be invested in biotechnology companies.
Three biotech-focused VC funds raised almost $1.2bn combined during the second quarter: Clarus Ventures closed a $500m fund in June; MPM Capital concluded a $400m fundraising; and Atlas Venture revealed a new $280m fund
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?